Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells

Many targets have been identified in solid tumors for antibody therapy but it is less clear what surface antigens may be most commonly expressed on disseminated tumor cells. Using malignant pleural effusions as a source of disseminated tumor cells, we compared a panel of 35 antigens for their cancer specificity, antigen abundance and functional significance. These antigens have been previously implicated in cancer metastasis and fall into four categories: (i) cancer stem cell, (ii) epithelial‐mesenchymal transition, (iii) metastatic signature of in vivo selection and (iv) tyrosine kinase receptors. We determined the antigen density of all 35 antigens on the cell surface by flow cytometry, which ranges from 3 × 103–7 × 106 copies per cell. Comparison between the malignant and benign pleural effusions enabled us to determine the antigens specific for cancer. We further chose six antigens and examined the correlation between their expression levels and tumor formation in immunocompromised mice. We concluded that CD24 is one of the few antigens that could simultaneously meet all three criteria of an ideal target. It was specifically and abundantly expressed in malignant pleural effusions; CD24high tumor cells formed tumors in mice at a faster rate than CD24low tumor cells, and shRNA‐mediated knockdown of CD24 in HT29 cells confirmed a functional requirement for CD24 in the colonization of the lung. Concomitant consideration of antigen abundance, specificity and functional importance can help identify potentially useful markers for disseminated tumor cells.

[1]  G. Kristiansen,et al.  CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. , 2011, Cancer research.

[2]  Derek Y. Chiang,et al.  Suppression of Lung Adenocarcinoma Progression by Nkx2-1 , 2011, Nature.

[3]  D. Theodorescu,et al.  Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. , 2011, The Journal of clinical investigation.

[4]  G. Lombardi,et al.  Diagnosis and Treatment of Malignant Pleural Effusion: A Systematic Literature Review and New Approaches , 2010, American journal of clinical oncology.

[5]  P. Athanassiadou,et al.  CD24 expression has a prognostic impact in breast carcinoma. , 2009, Pathology, research and practice.

[6]  V. Grantcharova,et al.  Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.

[7]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[8]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[9]  Peter Altevogt,et al.  Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. , 2008, Cancer research.

[10]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[11]  Kan Zhai,et al.  Diagnostic accuracy of tumor markers for malignant pleural effusion: a , 2007 .

[12]  H. Frierson,et al.  The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. , 2006, Cancer research.

[13]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[14]  G. Kristiansen,et al.  Tumour Biological Aspects of CD24, A Mucin-Like Adhesion Molecule , 2003, Journal of Molecular Histology.

[15]  P. Carter,et al.  Identification and validation of cell surface antigens for antibody targeting in oncology. , 2004, Endocrine-related cancer.

[16]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[17]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[18]  David L Rimm,et al.  Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. , 2003, Cancer research.

[19]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Bast,et al.  Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  P. Herrlich,et al.  CD44: From adhesion molecules to signalling regulators , 2003, Nature Reviews Molecular Cell Biology.

[22]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Yosef Yarden,et al.  Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.

[24]  S. Braun,et al.  Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[26]  P. Herrlich,et al.  CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. , 1991, Cancer research.

[27]  D. Scheinberg,et al.  Monoclonal antibody therapy of cancer. , 1990, Cancer chemotherapy and biological response modifiers.